daclatasvir


Also found in: Wikipedia.
Translations

daclatasvir

n daclatasvir m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The Phase 2a open-label study is being conducted at the Humanity & Health Research Centre, Humanity and Health Medical Group, in Hong Kong and will evaluate the safety, tolerability and preliminary efficacy of Cocrystal's CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhibitor, for the treatment of hepatitis C (HepC).
He explained that the generic medicine is a mixture of sofosbuvir and daclatasvir which are 98% effective in treatment of all genotypes of hepatitis C within 8 to 12 weeks without any side-effects.
Contrairement aux autres generiques de la maladie deja presents sur le marche marocain, notamment le Sofosvubir, le daclatasvir..., le nouveau medicament se veut [beaucoup moins que]revolutionnaire[beaucoup plus grand que], puisqu'il a la capacite de traiter en une seule dose tous les 6 genotypes de l'hepatite C.
The Phase 2a open-label study being conducted at Humanity & Health Research Centre, Humanity and Health Medical Group, in Hong Kong will evaluate the safety, tolerability and preliminary efficacy of Cocrystal's CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhibitor, for the treatment of hepatitis C.
Clinical review report: daclatasvir (Daklinza) in combination with other agents for the treatment of chronic hepatitis C (CHC) infection in adults with hepatitis C virus (HCV) genotype 1, and 2 infection and compensated liver disease (including cirrhosis) [Internet].
Daclatasvir, simeprevir, and ombitasvir-paritaprevir-ritonavir+dasabuvir, which are metabolized in the liver, can be used in CRF.
Though the Sofosbuvir and Daclatasvir combination is not the preferred first line regimen for the treatment of chronic HCV infection currently but because of its low cost, easy availability and low rate of adverse effects, it is the most commonly used pan-genotypic regimen for the treatment of chronic HCV infection in our local set up these days.
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
*Regimen-1: Tablet sofosbuvir (400 mg/day) + ledipasvir (90 mg/day) - for genotype 1 and 4 without cirrhosis *Regimen-2: Tablet Sofosbuvir (400 mg/day) + ledipasvir (90 mg/day) for patients with compensated cirrhosis for genotype 1 and 4 *Regimen-3: Tablet Sofosbuvir (400 mg/day) + tablet daclatasvir (60 mg/day) for genotype 1, 2, 3, and 4 without cirrhosis *Regimen-4: Tablet Sofosbuvir (400 mg/day) + tablet daclatasvir (60 mg/day) for patients with compensated cirrhosis for genotype 1, 3, and 4.